Castration-Resistant Prostate Carcinoma Clinical Trials

73 clinical trials for Castration-Resistant Prostate Carcinoma across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer — RECRUITING
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial — RECRUITING · PHASE2
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer — RECRUITING · PHASE1
• Imaging of Solid Tumors Using 18F-TRX — RECRUITING · PHASE1
• Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study — RECRUITING · PHASE2
• Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy — RECRUITING · PHASE1
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial — RECRUITING · NA
• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial — RECRUITING · PHASE2
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body — RECRUITING · PHASE3
• PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer — RECRUITING · PHASE2
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2
• Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis — ACTIVE_NOT_RECRUITING · PHASE1
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations — TERMINATED · PHASE2
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE2
• Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
• Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide — ACTIVE_NOT_RECRUITING · PHASE2
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression — TERMINATED · PHASE1
• Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
• Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer — TERMINATED · PHASE2
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy — ACTIVE_NOT_RECRUITING · PHASE3
• Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer — COMPLETED · PHASE2
• Efficacy of Ra-223 in PSMA PET Optimally Selected Patients — ACTIVE_NOT_RECRUITING · PHASE2
• Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer — TERMINATED · PHASE1
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate — ACTIVE_NOT_RECRUITING · PHASE1
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones — TERMINATED · PHASE2
• Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer — COMPLETED · PHASE2
• 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer — COMPLETED · PHASE3
• Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer — COMPLETED · PHASE2
• Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency — TERMINATED · PHASE2
• 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression — TERMINATED · PHASE1
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE1

Refine this search